Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 9/20 | 0.36 |
| ▸ | CA1 | P00915 | 6/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419967 | 0.93 | TP53 (0.50) | TP53RECQLFDPSCA1 | |
| SCHEMBL754167 | 0.91 | TP53 (0.48) | TP53FDPSCA2CA1 | |
| SCHEMBL754171 | 0.91 | TP53 (0.48) | TP53FDPSCA2CA1 | |
| SCHEMBL27960179 | 0.91 | TP53 (0.48) | TP53FDPSCA2CA1 | |
| SCHEMBL27731097 | 0.90 | TP53 (0.47) | TP53FDPSCA2CA1 | |
| SCHEMBL37544 | 0.86 | HDAC1 (0.39) | TP53RECQLFDPSCA2CA1 | |
| SCHEMBL193288 | 0.84 | HDAC1 (0.37) | TP53RECQLFDPSCA2CA1 | |
| Hydrochloric Acid SCHEMBL20590135 | 0.84 | HDAC1 (0.37) | TP53RECQLFDPSCA2CA1 | |
| SCHEMBL28560310 | 0.81 | TP53 (0.47) | TP53FDPSALDH1A1 | |
| SCHEMBL11759627 | 0.79 | TP53 (0.41) | TP53RECQLCA2CA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152078-B1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS INC (US) | 2021-01-13 | — | — | EP | claimed |
| CN-104800210-B | Preparation comprising clopidogrel and sulfoalkyl ether cyclodextrin and its application method | 锡德克斯药物公司 | 2019-08-06 | — | — | CN | claimed |
| CN-104800210-A | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS INC | 2015-07-29 | — | — | CN | claimed |
| US-9085525-B2 | Processes employing cyclodextrin derivative quaternary salts | MATOS JOSE R (US) | 2015-07-21 | — | — | US | claimed |
| CN-101686681-B | Formulations comprising clopidogrel and sulfoalkyl ether cyclodextrins and methods of use thereof | CYDEX PHARMACEUTICALS INC | 2015-04-01 | — | — | CN | claimed |
| US-20140046061-A1 | Processes Employing Cyclodextrin Derivative Quaternary Salts | MATOS JOSE R (US) | 2014-02-13 | — | — | US | claimed |
| US-8343995-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-20100292268-A1 | Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use | CYDEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | claimed |
| JP-2010525083-A | — | — | 2010-07-22 | — | — | JP | claimed |
| EP-2152078-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CyDex Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | claimed |
| WO-2008134600-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | claimed |
| WO-2008134601-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | claimed |
| EP-1742535-A4 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2008-10-15 | — | — | EP | claimed |
| US-20070175472-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2007-08-02 | — | — | US | claimed |
| EP-1755551-A2 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | Cydex Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| EP-1742535-A2 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | Cydex Inc. (US) | 2007-01-17 | — | — | EP | claimed |
| WO-2005117911-A2 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2005-12-15 | — | — | WO | claimed |
| WO-2005104712-A2 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050250738-A1 | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | claimed |
| US-20260115157-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260091073-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12527755-B2 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4620534-A2 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CyDex Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12390506-B2 | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-4591858-A2 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CyDex Pharmaceuticals, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-3939582-B1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2025-04-30 | — | — | EP | disclosed |
| US-11806402-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-3766493-B1 | METHOD FOR IMPROVING THE STABILITY OF CLOPIDOGREL USING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230255919-A1 | COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2023-08-17 | — | — | US | disclosed |
| US-20230233638-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | UNIVERSITY OF KANSAS | 2023-07-27 | — | — | US | disclosed |
| US-20220387444-A1 | COMPOSITION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND LATANOPROST | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-12-08 | — | — | US | disclosed |
| US-11464862-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-11433082-B2 | Composition containing sulfoalkyl ether cyclodextrin and latanoprost | CYDEX PHARMACEUTICALS, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11382944-B2 | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| CN-114053423-A | Sulfoalkyl ether cyclodextrin compositions | 锡德克斯药物公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3939582-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | Cydex Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3520779-B1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3270941-B1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210093727-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2021-04-01 | — | — | US | disclosed |
| EP-3766493-A1 | METHOD FOR IMPROVING THE STABILITY OF CLOPIDOGREL USING SULFOALKYL ETHER CYCLODEXTRIN | CyDex Pharmaceuticals, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-2152078-B1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS INC (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200330539-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-10-22 | — | — | US | disclosed |
| US-10780177-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200276314-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-09-03 | — | — | US | disclosed |
| US-10703826-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10702568-B2 | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200179400-A1 | COMPOSITION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND LATANOPROST | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-06-11 | — | — | US | disclosed |
| US-10668160-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| CN-110831588-A | Composition comprising cyclodextrin and busulfan | 锡德克斯药物公司 | 2020-02-21 | — | — | CN | disclosed |
| US-10512697-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2019-12-24 | — | — | US | disclosed |
| EP-3100728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10463677-B2 | Composition containing sulfoalkyl ether cyclodextrin and latanoprost | CYDEX PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190255000-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3520779-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CyDex Pharmaceuticals, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| CN-104800210-B | Preparation comprising clopidogrel and sulfoalkyl ether cyclodextrin and its application method | 锡德克斯药物公司 | 2019-08-06 | — | — | CN | disclosed |
| EP-3512511-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | Cydex Pharmaceuticals, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20190169316-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-06-06 | — | — | US | disclosed |
| US-20190070303-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-07 | — | — | US | disclosed |
| US-10202468-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| EP-2708225-B1 | DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin | CYDEX PHARMACEUTICALS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20180326090-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180318249-A1 | COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN | CYDEX PHARMACEUTICALS INC (US) | 2018-11-08 | — | — | US | disclosed |
| US-10117951-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-10117940-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-10111863-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3363430-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CyDex Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-10034947-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180133274-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-05-17 | — | — | US | disclosed |
| WO-2018053358-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| EP-3270941-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | Cydex Pharmaceuticals, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| US-9750822-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170172926-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-06-22 | — | — | US | disclosed |
| US-20170173178-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-06-22 | — | — | US | disclosed |
| EP-2952197-B1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CYDEX PHARMACEUTICALS INC (US) | 2017-04-26 | — | — | EP | disclosed |
| US-9623045-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9617352-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170007586-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-01-12 | — | — | US | disclosed |
| EP-3100728-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | Cydex Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160346405-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-12-01 | — | — | US | disclosed |
| WO-2016149685-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CYDEX PHARMACEUTICALS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-9399067-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| EP-2429291-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20160158384-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-06-09 | — | — | US | disclosed |
| US-20160058786-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-03-03 | — | — | US | disclosed |
| EP-2952197-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | Cydex Pharmaceuticals, Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| US-9200088-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9125945-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| CN-104800210-A | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS INC | 2015-07-29 | — | — | CN | disclosed |
| CN-104606681-A | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS INC | 2015-05-13 | — | — | CN | disclosed |
| EP-2335707-B1 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS INC (US) | 2015-05-06 | — | — | EP | disclosed |
| CN-101686681-B | Formulations comprising clopidogrel and sulfoalkyl ether cyclodextrins and methods of use thereof | CYDEX PHARMACEUTICALS INC | 2015-04-01 | — | — | CN | disclosed |
| EP-1945228-B9 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CYDEX PHARMACEUTICALS INC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150050355-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-02-19 | — | — | US | disclosed |
| CN-102625658-B | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS INC | 2015-01-28 | — | — | CN | disclosed |
| US-20150025243-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-01-22 | — | — | US | disclosed |
| US-20150005341-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-01-01 | — | — | US | disclosed |
| EP-2581078-B1 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS INC (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-1945228-B2 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CYDEX PHARMACEUTICALS INC (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2583668-B1 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8853236-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8846901-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8835407-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8829182-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2708225-A1 | DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin | CyDex Pharmaceuticals, Inc. (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20130288054-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2013-10-31 | — | — | US | disclosed |
| US-20130197105-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130184357-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CYDEX PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130129700-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2583668-A1 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CyDex Pharmaceuticals, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2581078-A1 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CyDex Pharmaceuticals, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8410077-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8383606-B2 | — | — | 2013-02-26 | — | — | US | disclosed |
| US-20130012534-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8343995-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8236782-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120164184-A1 | DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120136072-A1 | Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof | CYDEX PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| EP-2429291-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CyDex Pharmaceuticals, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8114438-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20120021013-A1 | Composition Containing Sulfoalkyl Ether Cyclodextrin and Latanoprost | CYDEX PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8049003-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110224232-A1 | Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2335707-A1 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CyDex Pharmaceuticals, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-1945228-B1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CYDEX PHARMACEUTICALS INC (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2268269-A2 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CyDex Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010132711-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100291056-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2010-11-18 | — | — | US | disclosed |
| US-20100292268-A1 | Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use | CYDEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010053487-A1 | COMPOSITION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND LATANOPROST | CYDEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100093663-A1 | Sulfoalkyl Ether Cyclodextrin Compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2152078-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CyDex Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-7635773-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7629331-B2 | Sulfoalkyl ether cyclodextrin; use in pharmaceutical dosage forms as solubilizer or stabilizer | CYDEX PHARMACEUTICALS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| WO-2009137611-A2 | TREATMENT OF PULMONARY FUNGAL INFECTION WITH VORICONAZOLE VIA INHALATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009134347-A2 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CYDEX PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270348-A1 | Sulfoalkyl Ether Cyclodextrin Compositions | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2009-10-29 | — | — | US | disclosed |
| US-20090123540-A1 | Sulfoalkyl ether cyclodextrin; use in pharmaceutical dosage forms as solubilizer or stabilizer | CYDEX PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009018069-A2 | MIXTURES OF CYCLODEXTRIN DERIVATIVES | CYDEX PHARMACEUTICALS, INC (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090011037-A1 | Improved flow and dissolution performance; use as solubilizer or stabilizer for drug formulations | CYDEX PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2008134600-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008134601-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1742535-A4 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1945228-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CyDex Pharmaceuticals, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070175472-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| WO-2007050075-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CYDEX, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| EP-1755551-A2 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | Cydex Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1742535-A2 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | Cydex Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1674098-A1 | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water | Schering Aktiengesellschaft (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005117911-A2 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005104712-A2 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005104712-A2 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050250738-A1 | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318249-A1 | COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN | SBDS, HBG1, CD99 | TP53 1079/4885RECQL 2487/4885FDPS 2231/4885 |
| US-20170007586-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | P2RY6, GP6, PFKP | TP53 2392/4885RECQL 708/4885FDPS 10/4885 |
| US-10702568-B2 | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same | GYS2, SDCBP, PYGL | TP53 181/4885RECQL 2524/4885FDPS 2767/4885 |
| US-20090011037-A1 | Improved flow and dissolution performance; use as solubilizer or stabilizer for drug formulations | ABCB11, SAE1, TBCD | TP53 610/4885RECQL 455/4885FDPS 948/4885 |
| US-20170173178-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885RECQL 1020/4885FDPS 1163/4885 |
| US-20150025243-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885RECQL 1020/4885FDPS 1163/4885 |
| US-20220387444-A1 | COMPOSITION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND LATANOPROST | DSC1, CRYZ, TBCD | TP53 1367/4885RECQL 996/4885FDPS 1405/4885 |
| US-20150005341-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | P2RY6, GP6, PFKP | TP53 2392/4885RECQL 708/4885FDPS 10/4885 |
| US-20130197105-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | DSP, DSC1, SAE1 | TP53 1837/4885RECQL 1671/4885FDPS 2349/4885 |
| US-20200276314-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | DSP, DSC1, SAE1 | TP53 1837/4885RECQL 1671/4885FDPS 2349/4885 |
| US-20260115157-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYP2C8, CYP3A43, SULT2A1 | TP53 2498/4885RECQL 2467/4885FDPS 129/4885 |
| US-20130012534-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | P2RY6, GP6, PFKP | TP53 2392/4885RECQL 708/4885FDPS 10/4885 |
| US-11382944-B2 | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same | GYS2, SDCBP, PYGL | TP53 181/4885RECQL 2524/4885FDPS 2767/4885 |
| US-20090123540-A1 | Sulfoalkyl ether cyclodextrin; use in pharmaceutical dosage forms as solubilizer or stabilizer | PDCD2L, SULT2A1, TBCD | TP53 826/4885RECQL 1151/4885FDPS 1288/4885 |
| US-20190255000-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYP2C8, CYP3A43, SULT2A1 | TP53 1441/4885RECQL 1108/4885FDPS 643/4885 |
| US-10111863-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | P2RY6, GP6, PFKP | TP53 2392/4885RECQL 708/4885FDPS 10/4885 |
| US-20160058786-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885RECQL 1020/4885FDPS 1163/4885 |
| US-20230233638-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | GYS2, SDCBP, PYGL | TP53 181/4885RECQL 2524/4885FDPS 2767/4885 |
| US-20120136072-A1 | Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof | SAE1, DSC1, SDC4 | TP53 879/4885RECQL 1150/4885FDPS 1852/4885 |
| US-20180326090-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885RECQL 1020/4885FDPS 1163/4885 |
| US-20100291056-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | P2RY6, GP6, PFKP | TP53 2392/4885RECQL 708/4885FDPS 10/4885 |
| US-10512697-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885RECQL 1020/4885FDPS 1163/4885 |
| US-12527755-B2 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | TPMT, GSTP1, ALB | TP53 1010/4885RECQL 2647/4885FDPS 651/4885 |
| US-20140046061-A1 | Processes Employing Cyclodextrin Derivative Quaternary Salts | PICALM, SI, PDCD2L | TP53 3057/4885RECQL 1588/4885FDPS 1600/4885 |
| US-10668160-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | DSP, DSC1, SAE1 | TP53 1837/4885RECQL 1671/4885FDPS 2349/4885 |
| US-11464862-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | DSP, DSC1, SAE1 | TP53 1837/4885RECQL 1671/4885FDPS 2349/4885 |
| US-20090270348-A1 | Sulfoalkyl Ether Cyclodextrin Compositions | SI, SULT1E1, SAE1 | TP53 1262/4885RECQL 2183/4885FDPS 2080/4885 |
| US-20130129700-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885RECQL 1020/4885FDPS 1163/4885 |
| US-20150050355-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | SAE1, SDC4, SPECC1L | TP53 787/4885RECQL 1132/4885FDPS 1979/4885 |
| US-10117951-B2 | Sulfoalkyl ether cyclodextrin compositions | SI, SULT1E1, SAE1 | TP53 1509/4885RECQL 2407/4885FDPS 2585/4885 |
| US-20100292268-A1 | Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885RECQL 1020/4885FDPS 1163/4885 |
| US-20190169316-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | SAE1, SDC4, SPECC1L | TP53 787/4885RECQL 1132/4885FDPS 1979/4885 |
| US-20050250738-A1 | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin | SORD, STS, SULT1A1 | TP53 3642/4885RECQL 2669/4885FDPS 1241/4885 |
| US-20100093663-A1 | Sulfoalkyl Ether Cyclodextrin Compositions | SI, SULT1E1, SAE1 | TP53 1509/4885RECQL 2407/4885FDPS 2585/4885 |
| US-20160158384-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | SI, SULT1E1, SAE1 | TP53 1509/4885RECQL 2407/4885FDPS 2585/4885 |
| US-20200330539-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | GYS2, SDCBP, PYGL | TP53 181/4885RECQL 2524/4885FDPS 2767/4885 |
| US-11433082-B2 | Composition containing sulfoalkyl ether cyclodextrin and latanoprost | DSC1, CRYZ, TBCD | TP53 1367/4885RECQL 996/4885FDPS 1405/4885 |
| US-20120164184-A1 | DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin | DSP, DSC1, SAE1 | TP53 1837/4885RECQL 1671/4885FDPS 2349/4885 |
| US-12390506-B2 | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same | GYS2, SDCBP, PYGL | TP53 181/4885RECQL 2524/4885FDPS 2767/4885 |
| US-20190070303-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | SI, SULT1E1, SAE1 | TP53 1509/4885RECQL 2407/4885FDPS 2585/4885 |
| US-20230255919-A1 | COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN | SBDS, HBG1, CD99 | TP53 1079/4885RECQL 2487/4885FDPS 2231/4885 |
| US-20120021013-A1 | Composition Containing Sulfoalkyl Ether Cyclodextrin and Latanoprost | DSC1, CRYZ, HPGDS | TP53 1388/4885RECQL 1045/4885FDPS 1392/4885 |
| US-20210093727-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | SI, SULT1E1, SAE1 | TP53 1509/4885RECQL 2407/4885FDPS 2585/4885 |
| US-20110224232-A1 | Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation | ERG28, STS, DPM1 | TP53 1423/4885RECQL 4265/4885FDPS 906/4885 |
| US-20200179400-A1 | COMPOSITION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND LATANOPROST | DSC1, CRYZ, TBCD | TP53 1367/4885RECQL 996/4885FDPS 1405/4885 |
| US-10034947-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885RECQL 1020/4885FDPS 1163/4885 |
| US-10780177-B2 | Sulfoalkyl ether cyclodextrin compositions | SI, SULT1E1, SAE1 | TP53 1509/4885RECQL 2407/4885FDPS 2585/4885 |
| US-20260091073-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | GYS2, COL1A1, COL14A1 | TP53 291/4885RECQL 1233/4885FDPS 3644/4885 |
| US-10463677-B2 | Composition containing sulfoalkyl ether cyclodextrin and latanoprost | DSC1, CRYZ, HPGDS | TP53 1388/4885RECQL 1045/4885FDPS 1392/4885 |
| US-11806402-B2 | Sulfoalkyl ether cyclodextrin compositions | SI, SULT1E1, SAE1 | TP53 1509/4885RECQL 2407/4885FDPS 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.